Jonathan Isgrig, OD
Optometrist · Bettendorf, IANPI 1376953042
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 33.8% of the total. Reporting peaked in 2023 at $812 and has fallen 73.6% since, to $215 in 2025. Among optometrist clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $25.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$593
- Alcon$272
- Coherus Oncology, Inc.$149
- Sun Pharmaceutical Industries Inc.$147
- Genentech USA, Inc.$125
- plus $763 from 15 others
What the payments were for
- Food & beverage$3,07799%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 43 | $1,047 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 30 | $593 |
| Alcon | 4 | $272 |
| Coherus Oncology, Inc. | 2 | $149 |
| Sun Pharmaceutical Industries Inc. | 13 | $147 |
| Genentech USA, Inc. | 1 | $125 |
| AbbVie(2 entities) | 8 | $119 |
| Aerie Pharmaceuticals, Inc. | 3 | $113 |
| Ivantis, Inc | 1 | $99 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $99 |
| Dompe US, Inc. | 1 | $70 |
| Johnson & Johnson Vision Care, Inc. | 3 | $66 |
| NEW World Medical,inc. | 1 | $44 |
| Oyster Point Pharma, Inc. | 2 | $43 |
| Tarsus Pharmaceuticals, Inc. | 1 | $21 |
| Glaukos Corporation | 1 | $18 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Rayner Intraocular Lenses Limited | 1 | $13 |
| Rxsight Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,095 in reported general payments places this provider in the 90th percentile of 559 optometrist providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 929 | $394,720 |
| RestasisCyclosporine | 121 | $119,443 |
| CombiganBrimonidine Tartrate/Timolol | 201 | $65,283 |
| Cyclosporine | 112 | $49,907 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 181 | $35,251 |
| RhopressaNetarsudil Mesylate | 61 | $28,407 |
| Latanoprost | 1,730 | $18,458 |
| Alphagan PBrimonidine Tartrate | 51 | $17,524 |
| Travoprost | 128 | $16,019 |
| XiidraLifitegrast | 16 | $15,309 |
| Brimonidine Tartrate | 204 | $14,266 |
| Brinzolamide | 67 | $12,641 |
| Timolol Maleate | 249 | $9,348 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 632 | $9,019 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 33 | $8,104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $119 | $596,9701,302 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $113 | $28,40761 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $1,047 | $19,37432 claims |
| AlconSimbrinza | $272 | $8,10433 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $593 | $6,09030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 559 optometrist providers in Iowa.
Other optometrist in Bettendorf
- Sara ButterworthCoralville$191K
- Ethan HuismanWaukee$111K
- Kelsi SawatzkyWest Des Moines$26K
- Heidi BellClive$19K
- Jennifer DenhartogClive$16K
- Wendianne WilsonUrbandale$14K
- Daniel KoenigAmes$11K
- Lexie FranzeenWest Des Moines$7K
- Mallori PhillipsGrimes$7K
- Gabrielle MageeWaukee$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.